Women | Men | |||
Value±SE | p-value | Value±SE | p-value | |
FEV1 % | n=37; obs=179 | n=27; obs=129 | ||
(Intercept) | 88.84±13.29 | <0.001 | 70.60±11.31 | <0.001 |
t1 | 5.27±1.95 | 0.008 | 3.47±2.02 | 0.090 |
t3 | 8.02±2.39 | 0.001 | 2.44±2.30 | 0.290 |
t6 | 7.89±2.58 | 0.003 | 1.84±2.33 | 0.432 |
t12 | 7.36±2.69 | 0.007 | 5.24±2.37 | 0.029 |
Age | -0.36±0.25 | 0.162 | 0.06±0.21 | 0.796 |
Tiffeneau % | n=36; obs=177 | n=27; obs=130 | ||
(Intercept) | 112.08±7.16 | <0.001 | 83.15±7.81 | <0.001 |
t1 | 1.50±1.11 | 0.178 | 3.54±1.34 | 0.010 |
t3 | 2.58±1.32 | 0.052 | 4.04±1.53 | 0.009 |
t6 | 2.69±1.39 | 0.055 | 1.67±1.58 | 0.292 |
t12 | 3.45±1.45 | 0.019 | 2.13±1.61 | 0.188 |
Age | -0.48±0.14 | 0.001 | 0.04±0.15 | 0.766 |
ACT score | n=34; obs=158 | n=22; obs=106 | ||
(Intercept) | 14.45±1.53 | <0.001 | 17.70±1.33 | <0.001 |
t1 | 4.10±0.69 | <0.001 | 3.96±0.72 | <0.001 |
t3 | 5.14±0.80 | <0.001 | 5.64±0.76 | <0.001 |
t6 | 5.62±0.77 | <0.001 | 5.68±0.77 | <0.001 |
t12 | 5.98±0.75 | <0.001 | 6.20±0.76 | <0.001 |
Age | 0.05±0.03 | 0.050 | 0.00±0.02 | 0.876 |
FEV1: forced expiratory volume in 1 s; t1, 3, 6, 12: visits at 1, 3, 6 and 12 months after treatment start; ACT: Asthma Control Test; obs: number of observations.